215 related articles for article (PubMed ID: 29123930)
21. Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: implications for treatment strategy.
Rohon P; Divoka M; Calabkova L; Mojzikova R; Katrincsakova B; Rusinakova Z; Lapcikova A; Raida L; Faber E; Jarosova M; Divoky V; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):187-90. PubMed ID: 21804629
[TBL] [Abstract][Full Text] [Related]
22. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
23. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
24. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.
Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Raj TVA; Priya G; Nair JKKM; Sreedharan H
Gene; 2019 Feb; 686():85-91. PubMed ID: 30399426
[TBL] [Abstract][Full Text] [Related]
25. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
Alikian M; Gale RP; Apperley JF; Foroni L
Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
[TBL] [Abstract][Full Text] [Related]
26. [Chronic myeloid leukemia with e6a2 fusion gene: a case report and literature review].
Li JJ; Yue LL; Zeng PY; Wu CY; Chen HL
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):299-302. PubMed ID: 38716604
[TBL] [Abstract][Full Text] [Related]
27. Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring.
Langabeer SE; McCarron SL; Kelly J; Krawczyk J; McPherson S; Perera K; Murphy PT
Case Rep Hematol; 2012; 2012():458716. PubMed ID: 22937329
[TBL] [Abstract][Full Text] [Related]
28. A novel
Zhou F; Jin R; Hu Y; Mei H
Mol Cytogenet; 2017; 10():19. PubMed ID: 28533818
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
[TBL] [Abstract][Full Text] [Related]
30. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?
Rumpold H; Webersinke G
Curr Cancer Drug Targets; 2011 Jan; 11(1):3-19. PubMed ID: 21062244
[TBL] [Abstract][Full Text] [Related]
32. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
[TBL] [Abstract][Full Text] [Related]
33. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
Soverini S; de Benedittis C; Mancini M; Martinelli G
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
[TBL] [Abstract][Full Text] [Related]
34. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Implications of Derivative Chromosome 9 Deletions in Patients with Advanced-Stage Chronic Myelogenous Leukemia.
Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Nair JKKM; Sreedharan H
J Environ Pathol Toxicol Oncol; 2018; 37(2):117-126. PubMed ID: 30055547
[TBL] [Abstract][Full Text] [Related]
36. A unique BCR-ABL1 transcript with the insertion of intronic sequence from BCR and ABL1 genes in a patient with Philadelphia-positive chronic myeloid leukemia: a case study.
Sadia H; Siddiqui RT; Nasim A
Cancer Genet Cytogenet; 2010 Aug; 201(1):57-61. PubMed ID: 20633771
[TBL] [Abstract][Full Text] [Related]
37. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
Antoszewska-Smith J; Pawlowska E; Blasiak J
Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
[TBL] [Abstract][Full Text] [Related]
38. A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
Yao J; Douer D; Wang L; Arcila ME; Nafa K; Chiu A
Leuk Res Rep; 2017; 7():17-19. PubMed ID: 28275539
[TBL] [Abstract][Full Text] [Related]
39. Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical
Petiti J; Lo Iacono M; Dragani M; Pironi L; Fantino C; Rapanotti MC; Quarantelli F; Izzo B; Divona M; Rege-Cambrin G; Saglio G; Gottardi EM; Cilloni D; Fava C
J Clin Med; 2020 May; 9(5):. PubMed ID: 32414125
[No Abstract] [Full Text] [Related]
40. Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical
Massimino M; Tirrò E; Stella S; Manzella L; Pennisi MS; Romano C; Vitale SR; Puma A; Tomarchio C; Di Gregorio S; Antolino A; Di Raimondo F; Vigneri P
Front Pharmacol; 2021; 12():669469. PubMed ID: 34276365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]